Navigation Links
Varian Medical Systems to Develop Interface Between the ARIA(TM) Oncology Information System and the Monarch250(TM) Proton Radiotherapy System From Still River Systems
Date:5/27/2008

PALO ALTO, Calif., May 27 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) and Still River Systems, Inc. today announced an agreement to develop an interface between Varian's ARIA(TM) Oncology Information System and Still River's Monarch250(TM) Proton Beam Radiotherapy (PBRT) System.

"ARIA is a powerful oncology information system that manages the clinical processes unique to radiotherapy treatments for cancer," said Corey Zankowski, Varian's senior director for product management. "In addition to providing a complete electronic medical record for oncology, ARIA is exceptional at recording and verifying the numerous treatment parameters and instruction sets required for complex radiotherapy treatments. Varian is committed to creating a completely open environment and ensuring connectivity between ARIA and most commonly-used radiation delivery devices, including proton treatment systems. As such, Varian is pleased to be developing, with the support of Still River, an interface with the Monarch250 proton therapy system."

"It is Varian's aim to bring the familiar workflow, look and feel of ARIA into the proton environment, to ease the transition of staff from conventional radiotherapy to proton therapy," adds James DeFilippi, Varian's business manager for integrated proton solutions.

Still River Systems will provide technical assistance to Varian engineers, who will develop the interface to allow important "record and verify" functionality across the two systems.

"We are developing the Monarch250 proton therapy system to support existing clinical processes. The Monarch250 ARIA interface will allow cancer centers to integrate proton therapy within their existing radiation therapy practices," adds Skip Ro
'/>"/>

SOURCE Varian Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cranberry Could Juice Up Ovarian Cancer Treatment
2. New Ovarian Cancer Drug Trial Under Way
3. Scientists demonstate link between genetic variant and effectiveness of smoking cessation meds
4. Pelvic Exams Can Help Spot Ovarian Cancer
5. Study fuels debate over whether exercise and body size influence ovarian cancer risk
6. Experimental drug boosts survival in recurrent ovarian cancer
7. New Ovarian Cancer Biomarker Research Act Introduced
8. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
9. More Fiber, Less Fat Help Prevent Ovarian Cancer
10. Media availability: low-fat dietary pattern may lower risk of ovarian cancer
11. The Silent Killer, Ovarian Cancer on Your Cancer Today (TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...Finding may lead to new therapies for preterm labo...- Researchers say they,ve found the switch that ac... childbirth, a finding that may lead to therapies ... normally binds the protein IP on the surface of t... inactive during pregnancy. , But researchers ...
(Date:11/21/2008)...Special meeting of shareholders to be held on Janu...e-FirstCall/ - Med-Emerg International Inc. ("MedE...iders of health services, announced today that it ...erior Court of Justice concerning its previously a...ursuant to which AIM Health Group Inc. ("AIM") wil...
(Date:11/21/2008)... HOUSTON(Nov. 21, 2008)The University of Texas Hea...ogram, Training Excellence in Aging Studies (TEXAS...hrough a prestigious $2 million award from the Don...tching funds., "This will allow us to teach geria... junior medical student to practicing physicians. ...
(Date:11/21/2008)...LOVELAND, Colo., Nov. 21 ...ced it will present at the New York Society of,Se... Pharma Conference on,December 2, 2008 at 1177 Av...The presentation is scheduled to begin at 9:35 a.m... be available via live webcast and for two weeks,...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4
...heir counterparts in the Health department of the ...g// a fast-food joint swarming with rats to contin...sible for the “shoddy audit” resigned Monday. The...d on videotape, created a national stir and prompt...
... with diabetes has another new risk- it heightens ...ou think and learn//, and may in fact set you on t... in the April issue of Archives of Neurology, one ... "Among cardiovascular risk factors, type 2 diabe...
...ed out to mark Mental Health Action Week, in Scotl...friends// who have experienced mental distress at ...at almost 90 percent of those suffering from menta...ing it to others, out of shame for appearing weak ...
... the Framingham Heart Study, dietary fat intake is...or 13 percent// of the study population with a spe...ne (APOA5), higher dietary fat was not related to ...gues analyzed several common gene variants known a...
Other Medicine News:Health News:Officials Indicted for Allowing a Fast Food Joint Teeming With Rats in New York to Function 2Health News:Diabetes May Bring You A Step Closer To Alzheimer’s Diseas 2Health News:Study Finds Dietary Fat Interacts With Genes 2Health News:Study Finds Dietary Fat Interacts With Genes 3
(Date:11/20/2008)...wswire/ -- The Scandinavian-based drug,developmen... studies on its,lead antimicrobial candidate LTX-...udies showed that the novel lytic peptidomimetic h...ntly better towards killing Staphylococcus,aureus...ndard drugs. In,addition to this it has proven ef...
(Date:11/19/2008)...tistical significance , , ISELIN, N.J., Nov...n (Nasdaq: PARS ) today announced results from i...sion (NE) drug delivery technology formulated with...i-center, randomized, double-blinded, placebo-cont...the Company,s 3% Diclofenac Diethanolamine NanoEmu...
(Date:11/19/2008)... Isogen, a contract development and,manufacturing... the first,phase launch of its contract facility ...ddress the process, facility and capacity problems...iched, low-volume clinical and,early-stage commer...anies can invest over $100 million and four years ...
(Date:11/18/2008)...rn more, make a donation or send a Christmas Seals...-USNewswire/ -- Millions will receive Christmas Se...an Lung Association. These decorative holiday stam...ing back to 1907 when the Lung Association led eff...mericans alive today have no vivid memories of how...
Breaking Medicine Technology:Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Isogen Launches Major New Facility to Address Global Biopharma Demand 2American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Desert Radiologists Sets Safe Practice Standards 17314 1Desert Radiologists Sets Safe Practice Standards 17314 2The Penis Diet 3A A Healthy Solution for Men Challenged by Erectile Dysfunction 17312 1The Penis Diet 3A A Healthy Solution for Men Challenged by Erectile Dysfunction 17312 2Chocolate bar shown to lower cholesterol 2976 1Chocolate bar shown to lower cholesterol 2976 2Health Plan One Closes 246 5 Million Series A Financing 17309 1Health Plan One Closes 246 5 Million Series A Financing 17309 2Health Plan One Closes 246 5 Million Series A Financing 17309 3
...linical Results Demonstrate Potential of ONCONASE ...June 27, 2007 /PRNewswire-FirstCall/ --,Alfacell C...NASE,the company,s lead drug candidate, is active...lls. , The pre-clinical in vitro and in vivo data ... 1: 107-116) through a collaboration,between Alfac...
...ORK--(BUSINESS WIRE)--Jun 27, 2007 - Gentium S.p.A...h clinical and preclinical,data that support the s...f action of Defibrotide in combination with antica...esented both an update,from the Company,s ongoing ...tory or relapsed multiple myeloma with Defibrotide...
Other Medicine Technology:In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 2In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 3Gentium's Defibrotide Seen as Active in Multiple Myeloma 2Gentium's Defibrotide Seen as Active in Multiple Myeloma 3
Zeiss offers a full range of filter sets for a variety of applications.
Dust covers for a variety of Zeiss microscopes
These objectives have more contrast than the DLL objectives for enhanced contrast with tissue culture specimens. These objectives are designed for use on inverted microscopes and therefore their mark
...that offers you much more than you have ever expec...e impressed by the outstanding quality, and functi... work as easy and safe as possible thus increasin... more time for the observation. , Contrasting...
Medicine Products: